A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

NCT07172867 · Withdrawn

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medications HT-6184 and semaglutide in adults with both type 2 diabetes and obesity.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Who can join Ages 18–65 · all sexes

Timeline Started 2026-01 · est. completion 2026-01

Where 1 site · United Arab Emirates

What this study is testing ClinicalTrials.gov NCT07172867 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

Treatments tested

HT-6184 Drug

2mg QD
HT-6184 Matching Placebo Drug

2mg QD
Semaglutide 1 mg Drug

Semaglutide 1 mg, every week

Main thing measured	Assess glycemic control using HbA1c (%)
Sponsor	Halia Therapeutics, Inc.
Conditions studied	Diabetes Mellitus, Type 2, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07172867 ↗